MAIA MAIA Biotechnology, Inc.
Financings ·
MAIA Biotechnology (NYSE American: MAIA) expects gross proceeds of approximately $695,000 from shares sold at $1.50 with warrants at $1.71. A director is among the buyers, and closing is expected May 29, 2025.
The smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far.
MAIA Biotechnology agreed on February 24, 2025 to sell 894,300 shares at $1.50 each, with warrants at $1.85, to accredited investors and certain directors. Combined gross proceeds are expected to be about $1.43 million, and the company's 2023 annual report carried a going-concern warning.
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO), is an investigational dual mechanism of action drug candidate that incorporates telomere targeting and immunogenicity. Ateganosine is being developed as a second- or later-line treatment for advanced non-small cell lung cancer (NSCLC) in patients who have progressed beyond existing checkpoint inhibitors. The Phase 2 THIO-101 trial, first dosed in Australia in July 2022, evaluates ateganosine given in sequence with cemiplimab (Libtayo), which the company receives at no cost from Regeneron under a clinical supply agreement. In July 2025 the company began an expansion of THIO-101 focused on third-line NSCLC patients. The company plans to seek accelerated approval in the United States for advanced NSCLC in 2026, based on THIO-101 data. A Phase 3 pivotal trial, THIO-104, started in 2025 and is designed for a direct comparison with chemotherapy in up to 300 patients. The former Phase 2 program THIO-102 has been divided into separate trials in hepatocellular carcinoma, colorectal cancer and small cell lung cancer, with trials planned to start in 2026 using tislelizumab from BeOne Medicines.
| Product or program | What it is | Stage |
|---|---|---|
| Ateganosine (THIO-101) | Telomere-targeting immunotherapy for advanced NSCLC after checkpoint inhibitors | Phase 2; fast track designation granted July 2025 |
| Ateganosine (THIO-104) | Ateganosine with a checkpoint inhibitor versus chemotherapy in third-line NSCLC | Phase 3 pivotal trial started in 2025 |
| Ateganosine (HCC, CRC, SCLC) | Ateganosine with tislelizumab in liver, colorectal and small cell lung cancers | Phase 2 trials planned to start in 2026 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | |
| Research and development | $453,745 | $10.0 million |
| Net income (loss) | -$22.4 million | -$23.3 million |
| Cash from operations | -$18.8 million | -$15.7 million |
| Cash and equivalents | $0 | $0 |
Our latest story on this, dated Feb 25, 2025: "MAIA Biotechnology prices $1.43 million private placement of shares and warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 28, 2025: "MAIA Biotechnology agrees to $695,000 private placement with warrants". The story links the filing or release it is based on. Read the story.
MAIA Biotechnology, Inc. trades under the ticker MAIA on AMEX.
MAIA Biotechnology, Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for MAIA Biotechnology, Inc. is 1878313. Its filings are on SEC EDGAR.
60,825,844 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-10.
Our directory records MAIA Biotechnology, Inc. under United States.
Our directory classifies MAIA Biotechnology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MAIA Biotechnology, Inc. is US5526411021.
aibio.space lists MAIA Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO), is an investigational dual mechanism of action drug candidate that incorporates telomere targeting and immunogenicity.
Ateganosine (THIO-101): Telomere-targeting immunotherapy for advanced NSCLC after checkpoint inhibitors Stage: Phase 2; fast track designation granted July 2025.
Ateganosine (THIO-104): Ateganosine with a checkpoint inhibitor versus chemotherapy in third-line NSCLC Stage: Phase 3 pivotal trial started in 2025.
MAIA Biotechnology, Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $18.8 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio